Maite Solas

Dr. Maite Solas

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Nutrients
Verified
Journal Article
Open access
PDF file
MJManuel H. Janeiro
Manuel H. Janeiro
Maria Javier RamirezMaria Javier Ramirez
Maria Javier Ramirez
Fermín I. MilagroFermín I. Milagro
Fermín I. Milagro
JMJ. Alfredo Martinez
J. Alfredo Martinez
MSMaite Solas
Maite Solas
Trimethylamine N-oxide (TMAO) is a molecule generated from choline, betaine, and carnitine via gut microbial metabolism. The plasma level of TMAO is determined by several factors including diet, gut microbial flora, drug administration and liver flavin monooxygenase activity. In humans, recent clinical studies evidence a positive correlation between elevated plasma levels of TMAO and an increased risk for major adverse cardiovascular events. A direct correlation between increased TMAO levels and neurological disorders has been also hypothesized. Several therapeutic strategies are being explored to reduce TMAO levels, including use of oral broad spectrum antibiotics, promoting the growth of bacteria that use TMAO as substrate and the development of target-specific molecules. Despite the accumulating evidence, it is questioned whether TMAO is the mediator of a bystander in the disease process. Thus, it is important to undertake studies to establish the role of TMAO in human health and disease. In this article, we reviewed dietary sources and metabolic pathways of TMAO, as well as screened the studies suggesting possible involvement of TMAO in the etiology of cardiovascular and neurological disorders, underlying the importance of TMAO mediating inflammatory processes. Finally, the potential utility of TMAO as therapeutic target is also analyzed.

12 January 2016 in Frontiers in Pharmacology
Verified
Journal Article
Open access
RYRamon Yarza
Ramon Yarza
SVSilvia Vela
Silvia Vela
MSMaite Solas
Maite Solas
Maria Javier RamirezMaria Javier Ramirez
Maria Javier Ramirez
C-Jun N-terminal kinases (JNKs) are a family of protein kinases that play a central role in stress signaling pathways implicated in gene expression, neuronal plasticity, regeneration, cell death and regulation of cellular senescence. It has been shown that there is a JNK pathway activation after exposure to different stressing factors, including cytokines, growth factors, oxidative stress, unfolded protein response signals or A peptides. Altogether, JNKs have become a focus of screening strategies searching for new therapeutic approaches to diabetes, cancer or liver diseases. In addition, activation of JNK has been identified as a key element responsible for the regulation of apoptotic apoptosis signals and therefore, it is critical for pathological occurring cell death associated with neurodegenerative diseases and, among them, with Alzheimer's disease (AD). In addition, in vitro and in vivo studies have reported alterations of JNK pathways potentially associated with pathogenesis and neuronal death in AD. JNK’s, particularly JNK3, not only enhance Aβ production, moreover it plays a key role in the maturation and development of neurofibrillary tangles. This review aims to explain the rationale behind testing therapies based on inhibition of JNK signalling for AD in terms of current knowledge about the pathophysiology of the disease. Keeping in mind that JNK3 is specifically expressed in the brain and activated by stress-stimuli, it is possible to hypothesize that inhibition of JNK3 might be considered as a potential target for treating neurodegenerative mechanisms associated with AD.

1 May 2016 in Cell
Verified
Journal Article
Closed access
AJAlexander Jais
Alexander Jais
MSMaite Solas
Maite Solas
HBHeiko Backes
Heiko Backes
BCBhagirath Chaurasia
Bhagirath Chaurasia
AKAndré Kleinridders
André Kleinridders
JBJens C. Brüning
Jens C. Brüning

1 March 2013 in Neurobiology of Aging
Verified
Journal Article
Closed access
MSMaite Solas
Maite Solas
PFPaul T. Francis
Paul T. Francis
Rafael FrancoRafael Franco
Rafael Franco
Maria Javier RamirezMaria Javier Ramirez
Maria Javier Ramirez

1 December 2017 in Current Opinion in Pharmacology
Verified
Journal Article
Closed access
MSMaite Solas
Maite Solas
Fermín I. MilagroFermín I. Milagro
Fermín I. Milagro
MRMaría J Ramírez
María J Ramírez
JMJ Alfredo Martínez
J Alfredo Martínez

Verified
Journal Article
Open access
PDF file
AEAmaia Ezkurdia
Amaia Ezkurdia
Maria Javier RamirezMaria Javier Ramirez
Maria Javier Ramirez
MSMaite Solas
Maite Solas
Alzheimer’s disease (AD) is the main type of dementia and is a disease with a profound socioeconomic burden due to the lack of effective treatment. In addition to genetics and environmental factors, AD is highly associated with metabolic syndrome, defined as the combination of hypertension, hyperlipidemia, obesity and type 2 diabetes mellitus (T2DM). Among these risk factors, the connection between AD and T2DM has been deeply studied. It has been suggested that the mechanism linking both conditions is insulin resistance. Insulin is an important hormone that regulates not only peripheral energy homeostasis but also brain functions, such as cognition. Insulin desensitization, therefore, could impact normal brain function increasing the risk of developing neurodegenerative disorders in later life. Paradoxically, it has been demonstrated that decreased neuronal insulin signalling can also have a protective role in aging and protein-aggregation-associated diseases, as is the case in AD. This controversy is fed by studies focused on neuronal insulin signalling. However, the role of insulin action on other brain cell types, such as astrocytes, is still unexplored. Therefore, it is worthwhile exploring the involvement of the astrocytic insulin receptor in cognition, as well as in the onset and/or development of AD.